Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated Unresectable Melanoma
Findings from the DREAMseq study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1650 results
Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and Survival in Locally Advanced Squamous Cell Carcinoma of Head and Neck Unfit for Cisplatin
PembroRad shows less toxicity from standard of care regimen in unfit patients
FLT3 Internal Tandem Duplication Measurable Residual Disease in Complete Remission Identifies Patients with AML with Profound Risk for Relapse and Death
Impact of NGS-based detection of FLT3 internal tandem duplication measurable residual disease on treatment outcome in newly diagnosed acute myeloid leukaemia
FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma
Evidence for efficacy is based on the results from the MajesTEC-1 study
EMA Adopts Positive Opinion for Pemetrexed Baxter
It is a generic of Alimta which has been authorised in the EU since 2004
Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes in Overall Use Even in Immunotherapy Era
Rate of systemic anticancer treatment use within 30 days of death across all cancer types did not change in recent years
First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years of Follow-Up in PD-L1–positive, Locally Advanced/Metastatic NSCLC Without EGFR/ALK Alterations
5-year outcomes with pembrolizumab versus chemotherapy in the KEYNOTE-042 study
Evaluation of Primary and Secondary Prevention of Oral Cancer
Findings from the IARC working group review of all relevant published studies
FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma
Evidence for efficacy is based on the results from the HIMALAYA study
EMA Recommends Extension of Therapeutic Indications for Zanubrutinib
New indication concerns the treatment of adult patients with CLL
Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast Cancers to PARP Inhibition
Activity of talazoparib in the context of homologous recombination pathway gene mutations beyond gBRCA1/2
Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to Temozolomide Alone in Advanced Pancreatic NETs
ECOG-ACRIN E2211 shows also that MGMT deficiency is associated with tumour response